HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22

HC Wainwright & Co. analyst Patrick R. Trucchio has maintained a Buy rating on Vir Biotechnology (NASDAQ: VIR) and raised the price target from $20 to $22. This adjustment reflects a positive outlook for the company's performance.